WO2013131010A3 - Function of chemokine receptor ccr8 in melanoma metastasis - Google Patents

Function of chemokine receptor ccr8 in melanoma metastasis Download PDF

Info

Publication number
WO2013131010A3
WO2013131010A3 PCT/US2013/028683 US2013028683W WO2013131010A3 WO 2013131010 A3 WO2013131010 A3 WO 2013131010A3 US 2013028683 W US2013028683 W US 2013028683W WO 2013131010 A3 WO2013131010 A3 WO 2013131010A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
function
ccr8
chemokine receptor
melanoma metastasis
Prior art date
Application number
PCT/US2013/028683
Other languages
French (fr)
Other versions
WO2013131010A2 (en
Inventor
Mihaela Skobe
Suvendu Das
Original Assignee
Icahn School Of Medicine At Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Of Medicine At Mount Sinai filed Critical Icahn School Of Medicine At Mount Sinai
Publication of WO2013131010A2 publication Critical patent/WO2013131010A2/en
Publication of WO2013131010A3 publication Critical patent/WO2013131010A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

This invention provides a method of treating a subject who has, or has been treated for, a solid tumor which comprises administering to the subject an antagonist of CCR8 receptors on the surface of tumor cells present in the solid tumor in an amount effective to reduce binding of CCL1 to the CCR8 receptors so as to thereby treat the subject. This invention also provides a method of reducing, or reducing the likelihood of, metastases in a subject who has, or has been treated for, a solid tumor which comprises administering to the subject an antagonist of CCR8 receptors on the surface of tumor cells present in the solid tumor in an amount effective to reduce binding of CCL1 to the CCR8 receptors so as to thereby reduce, or reduce the likelihood of, metastases in the subject.
PCT/US2013/028683 2012-03-02 2013-03-01 Function of chemokine receptor ccr8 in melanoma metastasis WO2013131010A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606169P 2012-03-02 2012-03-02
US61/606,169 2012-03-02

Publications (2)

Publication Number Publication Date
WO2013131010A2 WO2013131010A2 (en) 2013-09-06
WO2013131010A3 true WO2013131010A3 (en) 2013-11-14

Family

ID=49083467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/028683 WO2013131010A2 (en) 2012-03-02 2013-03-01 Function of chemokine receptor ccr8 in melanoma metastasis

Country Status (1)

Country Link
WO (1) WO2013131010A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9776979B2 (en) * 2013-09-26 2017-10-03 Sanford-Burnham Medical Research Institute EBI2 modulators
US10087259B1 (en) * 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CR20180047A (en) 2015-07-31 2018-03-07 Pfizer DERIVATIVES OF 1,1,1-TRIFLUORO-3-HYDROXIPROPAN-2-IL CARBAMATE AND DERIVATIVES OF 1,1,1-TRIFLUORO-4-HYDROXIBUTAN-2-IL CARBAMATE AS MAGL INHIBITORS
EP4092045A1 (en) * 2016-05-16 2022-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
RU2720203C1 (en) 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-trifluoro-3-hydroxypropane-2-ylcarbamate derivatives as magl inhibitors
RU2726631C1 (en) 2017-01-23 2020-07-15 Пфайзер Инк. Heterocyclic spiro compounds as magl inhibitors
DK3616720T3 (en) * 2017-03-29 2021-03-29 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT
CN108727400B (en) * 2017-05-24 2021-07-09 四川晶华生物科技有限公司 Compound for treating tumor
TW202039575A (en) * 2018-12-27 2020-11-01 日商鹽野義製藥股份有限公司 Novel anti-ccr8 antibody
MX2022008341A (en) 2020-01-06 2022-08-10 Vaccinex Inc Anti-ccr8 antibodies and uses thereof.
MX2022009947A (en) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof.
CN115989223A (en) * 2020-07-03 2023-04-18 南京艾美斐生物医药科技有限公司 Methods and compositions for targeting Tregs using CCR8 inhibitors
EP4267618A1 (en) 2020-12-24 2023-11-01 Vib Vzw Non-blocking human ccr8 binders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090214533A1 (en) * 2006-08-17 2009-08-27 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
US20110053969A1 (en) * 2005-04-04 2011-03-03 Astrazeneca Ab Novel diazasipiroakanes and their use for treatment of ccr8 mediated diseases
US20110150982A1 (en) * 2002-11-15 2011-06-23 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110150982A1 (en) * 2002-11-15 2011-06-23 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US20110053969A1 (en) * 2005-04-04 2011-03-03 Astrazeneca Ab Novel diazasipiroakanes and their use for treatment of ccr8 mediated diseases
US20090214533A1 (en) * 2006-08-17 2009-08-27 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity

Also Published As

Publication number Publication date
WO2013131010A2 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
WO2013131010A3 (en) Function of chemokine receptor ccr8 in melanoma metastasis
MX2021002406A (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor.
EP3736294A3 (en) Cd73 blockade
WO2013056148A3 (en) Scd1 antagonists for treating cancer
MX2016007885A (en) Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody.
PH12014501108A1 (en) Anti-il-36r antibodies
WO2012099973A3 (en) Compositions and methods for treating cancer
MX361242B (en) Methods of treating immune disorders with single domain antibodies against tnf-alpha.
MX2014011134A (en) Carbamate compounds and of making and using same.
EA201400625A1 (en) ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION
WO2014089169A3 (en) Immunotherapy with binding agents
WO2012061537A3 (en) Methods for treating hair loss disorders
PH12014502406B1 (en) Anti-il-23p19 antibodies
PH12015502126A1 (en) Human pac1 antibodies
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
WO2011130347A3 (en) Methods for enhancing axonal regeneration
MX2013006875A (en) Anti-notch1 antibodies.
MX2014004074A (en) Methods of treating liver conditions using notch2 antagonists.
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
WO2013090635A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
MX2014001766A (en) Neuregulin antibodies and uses thereof.
NZ722600A (en) Methods of treating mild brain injury
WO2012094328A3 (en) Hedgehog antagonists having zinc binding moieties
PT2770979E (en) Improved cross-linking composition delivered by iontophoresis, useful for the treatment of keratoconus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13754777

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13754777

Country of ref document: EP

Kind code of ref document: A2